C
Castle Biosciences, Inc.
CSTL
$20.21
-$0.38-1.85%
C
Hold
3/3/2025Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to C from D+ on 3/3/2025 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 322.65% from $2.27M to $9.59M, earnings per share increased from $0.08 to $0.3141, and operating cash flow increased 4.4% from $23.34M to $24.37M.
Castle Biosciences, Inc. (CSTL) was upgraded to C from D+ on 3/3/2025 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 322.65% from $2.27M to $9.59M, earnings per share increased from $0.08 to $0.3141, and operating cash flow increased 4.4% from $23.34M to $24.37M.
D
Sell
2/25/2025Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 2/25/2025 due to an increase in the valuation index.
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 2/25/2025 due to an increase in the valuation index.
D
Sell
2/6/2025Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 2/6/2025 due to a decline in the total return index and valuation index.
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 2/6/2025 due to a decline in the total return index and valuation index.
D
Sell
1/22/2025Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 1/22/2025 due to an increase in the valuation index and volatility index.
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 1/22/2025 due to an increase in the valuation index and volatility index.
D
Sell
12/20/2024Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 12/20/2024 due to a decline in the total return index.
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 12/20/2024 due to a decline in the total return index.
D
Sell
11/6/2024Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D- on 11/6/2024 due to a substantial increase in the efficiency index, total return index and volatility index. Total capital increased 4.17% from $449.08M to $467.8M.
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D- on 11/6/2024 due to a substantial increase in the efficiency index, total return index and volatility index. Total capital increased 4.17% from $449.08M to $467.8M.
D
Sell
8/23/2024Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 8/23/2024 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 451.1% from -$6.84M to $24M, earnings per share increased from -$0.0922 to $0.31, and EBIT increased 191.61% from -$5.47M to $5.01M.
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 8/23/2024 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 451.1% from -$6.84M to $24M, earnings per share increased from -$0.0922 to $0.31, and EBIT increased 191.61% from -$5.47M to $5.01M.
E
Sell
7/30/2024Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to E+ from D- on 7/30/2024 due to a decline in the volatility index and valuation index.
Castle Biosciences, Inc. (CSTL) was downgraded to E+ from D- on 7/30/2024 due to a decline in the volatility index and valuation index.
D
Sell
7/11/2024Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index and valuation index.
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 7/11/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/25/2024Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to E+ from D- on 6/25/2024 due to a decline in the valuation index.
Castle Biosciences, Inc. (CSTL) was downgraded to E+ from D- on 6/25/2024 due to a decline in the valuation index.
D
Sell
11/3/2023Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 11/3/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 232.38% from -$3.79M to $5.01M, earnings per share increased from -$0.7024 to -$0.26, and EBIT increased 54.44% from -$21.16M to -$9.64M.
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 11/3/2023 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 232.38% from -$3.79M to $5.01M, earnings per share increased from -$0.7024 to -$0.26, and EBIT increased 54.44% from -$21.16M to -$9.64M.
E
Sell
10/26/2023Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to E+ from D- on 10/26/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 8.62 to 7.62.
Castle Biosciences, Inc. (CSTL) was downgraded to E+ from D- on 10/26/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 8.62 to 7.62.
D
Sell
3/14/2023Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 9.04 to 7.81.
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 9.04 to 7.81.
D
Sell
2/23/2023Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 2/8/2023 due to a large decline in the total return index and valuation index.
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 2/8/2023 due to a large decline in the total return index and valuation index.
D
Sell
5/31/2022Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 05/31/2022.
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 05/31/2022.
D
Sell
5/13/2022Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 13.94 to 8.32.
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 13.94 to 8.32.
D
Sell
5/5/2022Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
D
Sell
4/20/2022Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index and total return index.
Castle Biosciences, Inc. (CSTL) was downgraded to D- from D on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
1/3/2022Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 1/3/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 34.13% from -$8.79M to -$11.79M, and total capital declined 1.01% from $415.92M to $411.71M.
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 1/3/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 34.13% from -$8.79M to -$11.79M, and total capital declined 1.01% from $415.92M to $411.71M.
D
Sell
8/25/2021Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 8/25/2021 due to a noticeable increase in the total return index and valuation index.
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 8/25/2021 due to a noticeable increase in the total return index and valuation index.
D
Sell
8/10/2021Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 8/10/2021 due to a noticeable decline in the volatility index, growth index and valuation index. EBIT declined 105.65% from -$4.28M to -$8.81M, earnings per share declined from -$0.1718 to -$0.3504, and operating cash flow declined 77.31% from -$3.63M to -$6.44M.
Castle Biosciences, Inc. (CSTL) was downgraded to D from D+ on 8/10/2021 due to a noticeable decline in the volatility index, growth index and valuation index. EBIT declined 105.65% from -$4.28M to -$8.81M, earnings per share declined from -$0.1718 to -$0.3504, and operating cash flow declined 77.31% from -$3.63M to -$6.44M.
D
Sell
3/29/2021Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to D+ from C- on 3/29/2021 due to a noticeable decline in the total return index and volatility index.
Castle Biosciences, Inc. (CSTL) was downgraded to D+ from C- on 3/29/2021 due to a noticeable decline in the total return index and volatility index.
C
Hold
3/12/2021Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to C- from D+ on 3/12/2021 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 85.45% from -$2.96M to -$430, and total revenue increased 13.68% from $15.22M to $17.3M.
Castle Biosciences, Inc. (CSTL) was upgraded to C- from D+ on 3/12/2021 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 85.45% from -$2.96M to -$430, and total revenue increased 13.68% from $15.22M to $17.3M.
D
Sell
10/19/2020Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 10/19/2020 due to a noticeable increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.29 to 0.16.
Castle Biosciences, Inc. (CSTL) was upgraded to D+ from D on 10/19/2020 due to a noticeable increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.29 to 0.16.
D
Sell
8/3/2020Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 8/3/2020 due to an increase in the total return index, efficiency index and volatility index. Total capital increased 2.76% from $110.24M to $113.28M.
Castle Biosciences, Inc. (CSTL) was upgraded to D from D- on 8/3/2020 due to an increase in the total return index, efficiency index and volatility index. Total capital increased 2.76% from $110.24M to $113.28M.
D
Sell
4/1/2020Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 4/1/2020 due to a large increase in the efficiency index, solvency index and valuation index. Total capital increased 2.79% from $107.24M to $110.24M.
Castle Biosciences, Inc. (CSTL) was upgraded to D- from E+ on 4/1/2020 due to a large increase in the efficiency index, solvency index and valuation index. Total capital increased 2.79% from $107.24M to $110.24M.
E
Sell
1/2/2020Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to E+ from E on 1/2/2020 due to a significant increase in the solvency index, efficiency index and growth index. EBIT increased 628.97% from $607.6 to $4.43M, net income increased 560.9% from -$1.27M to $5.85M, and the quick ratio increased from 2.32 to 11.57.
Castle Biosciences, Inc. (CSTL) was upgraded to E+ from E on 1/2/2020 due to a significant increase in the solvency index, efficiency index and growth index. EBIT increased 628.97% from $607.6 to $4.43M, net income increased 560.9% from -$1.27M to $5.85M, and the quick ratio increased from 2.32 to 11.57.
E
Sell
11/5/2019Upgraded
Castle Biosciences, Inc. (CSTL) was upgraded to E from E- on 11/5/2019 due to a noticeable increase in the volatility index and total return index.
Castle Biosciences, Inc. (CSTL) was upgraded to E from E- on 11/5/2019 due to a noticeable increase in the volatility index and total return index.
E
Sell
10/21/2019Downgrade
Castle Biosciences, Inc. (CSTL) was downgraded to E- from E on 10/21/2019 due to a decline in the volatility index and total return index.
Castle Biosciences, Inc. (CSTL) was downgraded to E- from E on 10/21/2019 due to a decline in the volatility index and total return index.
E
Sell
10/17/2019None
Castle Biosciences, Inc. (CSTL) was downgraded to E from U on 10/17/2019.
Castle Biosciences, Inc. (CSTL) was downgraded to E from U on 10/17/2019.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
